2020
January
Special delivery! An oncolytic virus encoding IL-7 and IL-12
January 29, 2020
The immune status of the tumor microenvironment (TME) is known to be a key factor influencing the success or failure of cancer immunotherapy. In an effort to improve the immune status of the TME, Nakao et al. tested the intratumoral delivery of oncolytic viruses encoding IL-7 and IL-12, and saw encouraging local and...
PD-1 in myeloid cells prevents tumor control
January 22, 2020
Aiming to uncover the role that the expression of PD-1 in various cell types plays in antitumor immunity, Strauss et al. analyzed the effects of selective PD-1 ablation in myeloid cells and T cells, and surprisingly found that knockout of PD-1 in myeloid cells, but not in T cells, was crucial for an...
Kickstarting the cancer immunity cycle with AGI-134
January 15, 2020
The cancer immunity cycle starts and ends with cancer cell death, and inducing cancer cell death at the site of a tumor to kickstart antitumor immunity is a developing strategy in cancer immunotherapy. One approach that has been explored to induce cancer cell death in situ is the introduction of α-Gal epitopes, which...
Stem-like CD8+ T cells cozy up within tumors before launching an attack
January 8, 2020
Since the infiltration of CD8+ T cells into tumors predicts survival and response to immunotherapy in many patients, Jansen et al. examined the CD8+ T cell response against human cancer in order to understand why some tumors have high CD8+ T cell infiltration while others do not, and to uncover the mechanisms behind...
